T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.
1 - 80 . (canceled)
81 . A soluble single-chain T cell receptor fusion molecule comprising a T cell receptor and a cytokine or fragment thereof connected by a first peptide linker, wherein the soluble single-chain T cell receptor has one recognition binding site and the cytokine or fragment thereof has a different recognition binding site, wherein the soluble single-chain T cell receptor comprises an α variable chain and a β variable chain TCR covalently linked together by a second peptide linker and a β constant domain covalently linked to the β variable chain.
82 . The soluble single chain T cell receptor fusion molecule of claim 81 , wherein the fusion molecule comprises a sequence of covalently linked subunits comprising the sequence: (NH2)-TCR-Vα—second peptide linker—TCR-Vβ—TCR-Cβ—first peptide linker—cytokine or fragment thereof.
83 . The soluble T cell receptor fusion molecule of claim 81 , wherein the cytokine or fragment thereof is specific for recognition of an effector cell.
84 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises an IL-2 cytokine or a fragment thereof.
85 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises an IL-10 cytokine or a fragment thereof.
86 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises a chemokine or a fragment thereof.
87 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises a growth factor or a fragment thereof.
88 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises GCSF or a fragment thereof.
89 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises GMCSF or a fragment thereof.
90 . The soluble T cell receptor fusion molecule of claim 81 , wherein the biologically active polypeptide comprises a protein toxin domain or a fragment thereof.
91 . The soluble single-chain T cell receptor fusion molecule of claim 81 , wherein at least one of the first and second peptide linkers includes from about 7 to 20 amino acids.
92 . The soluble single-chain T cell receptor fusion molecule of claim 81 , wherein the first and second peptide linkers includes from about 8 to 16 amino acids.
93 . The soluble single-chain T cell receptor fusion molecule of claim 92 , wherein at least one of the first and second peptide linkers consist of alanine, serine and glycine to provide for flexibility.
94 . A therapeutic composition for treatment of disorders comprising a therapeutically effective amount of the T cell receptor fusion molecule of claim 81 and a sterile, pharmaceutically acceptable carrier vehicle.